Acute coronary syndrome and recurrent colitis as immune-related adverse events in a lung cancer patient

J Oncol Pharm Pract. 2020 Jan;26(1):252-255. doi: 10.1177/1078155219865596. Epub 2019 Aug 5.


Immune checkpoint inhibitors have become a target for pharmacological research in lung cancer. Immune-related adverse events (irAEs) such as pneumonitis, colitis, hepatitis and endocrinopathies have been well characterized in immune checkpoint inhibitors, but coronary toxicities, like acute coronary syndrome, are poorly described. Herein, we report a possible acute coronary syndrome as immune-related adverse event in a lung cancer patient.

Keywords: Nivolumab; acute coronary syndrome; immune-relate adverse events; lung cancer; recurrent colitis.

Publication types

  • Case Reports

MeSH terms

  • Acute Coronary Syndrome / chemically induced*
  • Aged
  • Antineoplastic Agents, Immunological / adverse effects*
  • Colitis / chemically induced*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Male
  • Nivolumab / adverse effects*
  • Recurrence


  • Antineoplastic Agents, Immunological
  • Nivolumab